Proteome Sciences PLC - Drug development services provider - Secures a contract from major US academic group to evaluate changes on the proteome and phospho-proteome of tissue and blood samples taken from people with and without a neurodegenerative disease. The contract’s value exceeds £500,000. Proteome refers to entire set of proteins in a cell or organism.

Chief Commercial Officer Richard Dennis said: ‘We are pleased that the SysQuant workflows that we offer has been selected by our client to quantitate the proteomic/phosphoproteomic changes in these research samples.’

Current stock price: 4.45 pence, up 8.5% on Thursday morning in London.

12-month change: down 48%

Copyright 2022 Alliance News Limited. All Rights Reserved